AUTHOR=Youssef David Edward , Handler Stephanie S. , Richards Susan Marjorie , Sheppard Catherine Anne , Smith Jenna , Tillman Kathryn , Pietrosanu Matthew , Kirkpatrick Edward , Bates Angela 

TITLE=Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

JOURNAL=Frontiers in Pediatrics

VOLUME=Volume 11 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1055131

DOI=10.3389/fped.2023.1055131

ISSN=2296-2360

ABSTRACT=Introduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 hours), stable pharmacokinetics and pharmacodynamics, and minimal adverse effects. However, the utility of tadalafil suspensions in this setting has not been widely explored due to a lack of clinical experience. We present a multicenter experience that details the safety and tolerability of a tadalafil suspension, either alone or in combination with another vasodilator, for the management of pediatric pulmonary hypertension (PH).